4.3 Article

2011 White Paper on Recent Issues in Bioanalysis and Regulatory Findings from Audits and Inspections

期刊

BIOANALYSIS
卷 3, 期 18, 页码 2081-2096

出版社

FUTURE SCI LTD
DOI: 10.4155/BIO.11.192

关键词

-

资金

  1. US FDA
  2. Brazil ANVISA
  3. European Medicines Agency
  4. Health Canada TPD
  5. France AFSSAPS
  6. Japan MHLW-NIHS
  7. Austria AGES PharmMed
  8. European Bioanalysis Forum
  9. Pharma Medica Research
  10. GYROS
  11. WIL Reseach Company
  12. Cetero Research
  13. Intertek Pharmaceutical Services
  14. Algorithme Pharma
  15. Bruker
  16. Waters
  17. iStudy Reporter Bioanalytics
  18. AB Sciex
  19. Zef Scientific
  20. Tandem Labs
  21. Advion, Worldwide Clinical Trials
  22. PRA International
  23. mSpec Group
  24. ICON
  25. Celerion
  26. Parker Balston
  27. Peak Scientific
  28. Bioanalysis Journal
  29. KCAS, Thermo Scientific
  30. MPI Research
  31. PPD
  32. ICF

向作者/读者索取更多资源

The 5th Workshop on Recent Issues in Bioanalysis (WRIB) was organized by the Calibration and Validation Group as a 2-day full immersion workshop for pharmaceutical companies, CROs and regulatory agencies to discuss, review, share perspectives, provide potential solutions and agree upon a consistent approach to recent issues in the bioanalysis of both small and large molecules. High quality, better compliance to regulations and scientific excellence are the foundation of this workshop. As in the previous editions of this significant event, recommendations were made and a consensus was reached among panelists and attendees, including industry leaders and regulatory experts representing the global bioanalytical community, on many 'hot' topics in bioanalysis. This 2011 White Paper is based on the conclusions from this workshop, and aims to provide a practical reference guide on those topics.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据